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Madurella mycetomatis Is Not Susceptible to the
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Eumycetoma caused by Madurella mycetomatis is treated surgically and with high doses of ketoconazole.
Therapeutic responses are poor, and recurrent infections are common. In search of therapeutic alternatives in
the treatment of mycetoma, we determined the in vitro susceptibilities of M. mycetomatis isolates against
caspofungin, anidulafungin, and micafungin. As a comparator fungus, Aspergillus fumigatus was used. Minimal
effective concentrations (MECs) and MICs were assessed and compared to those of ketoconazole. M. myce-
tomatis isolates were not susceptible to the echinocandins.
Eumycetoma is a subcutaneous disease caused by a variety
of microorganisms, both bacteria and fungi. The most common
causative fungus is Madurella mycetomatis. After surgical de-
bridement, eumycetoma is usually treated for extended periods
of time with high doses of either itraconazole (ITZ) or keto-
conazole (KTZ), which can result in hepatoxicity. In order to
identify alternative antifungal therapies, the susceptibilities of
M. mycetomatis to other antifungal agents (amphotericin B,
5-flucytosine, fluconazole, and voriconazole) have been deter-
mined before and compared to the obtained susceptibilities to
ITZ and KTZ. M. mycetomatis remains most susceptible to-
ward the azoles and amphotericin B; no activity was seen with
5-flucytosine (10).
The echinocandins are a relatively new class of antifungal
agents, with caspofungin (CAS), anidulafungin (ANI), and mi-
cafungin (MICA) as its licensed representatives. Echinocan-
dins inhibit the synthesis of 1,3--glucan, the main component
of the fungal cell wall. In Candida spp., the echinocandins are
fungicidal, but in molds such as Aspergillus species, the echi-
nocandins show fungistatic activity. Limited activity has been
noted against zygomycetes, basidiomycetes, and some Scedos-
porium species (12). Only one study addressed the susceptibil-
ity of M. mycetomatis to the echinocandins. In that study, the
susceptibilities of only 3 isolates of M. mycetomatis against ANI
were determined (6). No data are available for the other echi-
nocandins.
We determined the in vitro susceptibilities of 17 clinical M.
mycetomatis isolates to CAS, ANI, and MICA in comparison to
the in vitro susceptibility of A. fumigatus ATCC 204305. All M.
mycetomatis isolates were identified by internal transcribed
spacer (ITS) sequencing. For M. mycetomatis, as a comparator,
MICs were also determined for KTZ (Janssen Pharmaceuti-
cals, Beerse, Belgium).
MICs were determined independently in triplicate in
RPMI medium by using the previously reported 2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-
2H-tetrazolium hydroxide (XTT) assays for M. mycetomatis
and A. fumigatus as described elsewhere (1, 10, 11). For A.
fumigatus, conidia were exposed to the antifungal agents, while
for M. mycetomatis, a hyphal inoculum was used, since this
fungus does not usually sporulate on agar plates. In the past,
hyphal inocula were also prepared for A. fumigatus, and it
appeared that hyphal fragments show antifungal agent suscep-
tibilities similar to those of conidia (11). The MIC endpoints
for each antifungal agent were defined as the first concentra-
tions resulting in a spectrophotometric reduction of more than
80%. The minimal effective concentration (MEC) endpoint
was determined as the first concentration in which altered
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TABLE 1. Susceptibilities of M. mycetomatis and A. fumigatus to
ketoconazole, caspofungin, anidulafungin, and micafungin
Species Strain
MIC (MEC) (mg/liter)a
KTZ CAS ANI MICA
M. Mm31 0.063 64 128 128
mycetomatis Mm35 1 128 128 128
Mm36 0.063 128 128 128
Mm39 0.031 64 128 128
Mm41 0.125 16 0.5 8
Mm43 0.063 128 128 128
Mm45 0.25 64 128 128
Mm46 0.016 64 128 128
Mm49 0.031 32 128 128
Mm50 0.063 128 128 128
Mm52 0.25 128 128 128
Mm54 0.031 64 128 128
Mm55 0.25 128 128 128
Mm64 0.063 64 128 128
Mm68 0.125 64 128 128
Mm73 0.063 64 128 128
Mm83 0.125 128 128 128
A. fumigatus ATCC
204305
ND 128 (0.125) 128 (0.007) 128 (0.007)
a The in vitro antifungal susceptibilities of M. mycetomatis and A. fumigatus to
ketoconazole (KTZ), caspofungin (CAS), anidulafungin (ANI), and micafungin
(MICA) are shown. For all 17 M. mycetomatis isolates, the MICs are given; for
the quality control A. fumigatus ATCC 204305 strain, both the MIC and the
MEC (in parentheses) are given. ND, not done.
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growth was noticed. Twofold-increasing drug concentrations
were used, and they ranged from 0.016 mg/liter to 16 mg/liter
for KTZ and 0.007 mg/liter to 128 mg/liter for CAS (Merck
and Company, Rahway, NJ), ANI (Pfizer BV, Capelle aan de
Ijsel, Netherlands), and MICA (Astellas Pharma, Leiderdorp,
Netherlands). KTZ, CAS, and ANI were diluted in dimethyl
sulfoxide (DMSO), and MICA was diluted in normal saline.
The final concentration of DMSO per inoculum was as stated
by the CLSI (2).
To determine the -1,3-glucan concentration, microcentri-
fuge tubes were inoculated with 100 l of an M. mycetomatis
hyphal suspension in RPMI or an A. fumigatus conidial sus-
pension in RPMI as described above. After incubation with the
antifungal agents (7 days at 37°C for M. mycetomatis or 48 h for
A. fumigatus), the mycelium was freeze-dried, and 250 l of 1
M NaOH was added. This mixture was sonicated with a mi-
croprobe for 15 s at 26 m and incubated at 52°C for 30 min.
Glucan levels were determined by aniline blue fluorescence as
described elsewhere, by using curdlan (Sigma) as a positive
control (3, 8).
In accordance with previously published MICs for M. myce-
tomatis, all strains were strongly inhibited by KTZ, the drug of
choice to treat eumycetoma in Sudan (Table 1). MICs for KTZ
ranged from 0.016 mg/liter to 1 mg/liter. A concentration of
0.25 mg/liter was needed to inhibit the growth of 90% of the
isolates (Table 1). Most of the M. mycetomatis strains were not
inhibited in growth by the echinocandins (Table 1). Most MICs
for CAS were 128 mg/liter, while the MICs of ANI and MICA
were above 128 mg/liter (Table 1). As is seen in Table 1, only
for isolate Mm41 were lower MICs obtained, and these were
16 mg/liter for CAS, 0.5 mg/liter for ANI, and 8 mg/liter for
MICA. The results shown here are different from previously
published susceptibility data for M. mycetomatis. In that study,
the spores of three sporulating strains of M. mycetomatis were
used. Conidia were harvested and exposed to ANI, and MICs
of 1 mg/liter were obtained (6). The species M. mycetomatis is
not well characterized, and in the past, misidentifications have
occurred. One of the key features of this species is its lack of
sporulation on agar plates. To ascertain that only M. myce-
tomatis isolates were used in the present study, all isolates were
identified by ITS sequencing. None of our isolates did sporu-
late, and we therefore used hyphal fragments to determine the
in vitro susceptibilities against the echinocandins. Our inocu-
lation procedure, therefore, differs from that of Odabasi et al.
(6), which could explain the discrepancy in results. Another
explanation could be that the three isolates of Odabasi et al.
resembled isolate Mm41, which in our study also appeared to
be susceptible to anidulafungin. Since the isolates of Odabasi
et al. were not used in our study, we cannot exclude this
possibility.
In the present study, Mm41 behaved different from the other
M. mycetomatis isolates with regard to echinocandin suscepti-
FIG. 1. Effect of echinocandins on M. mycetomatis and A. fumigatus. (A) M. mycetomatis growth control. (B) M. mycetomatis exposed to 1
mg/liter CAS. (C) A. fumigatus growth control. (D) A. fumigatus exposed to 1 mg/liter CAS. (E) M. mycetomatis -1,3-D-glucan concentration of
strain Mm55 as determined by the aniline blue assay. -1,3-D-Glucan concentrations were corrected to the number of viable cells with the XTT
assay by the following formula: (amount of beta-glucan measured)  (number of viable cells in tested well/number of viable cells in growth control).
Each point represents the mean -1,3-D-glucan concentration with the standard deviation. (F) A. fumigatus -1,3-D-glucan concentration as
determined by the aniline blue assay. -1,3-D-Glucan concentrations were corrected to the number of viable cells with the XTT assay. Each point
represents the mean -1,3-D-glucan concentration with the standard deviation. CAS, caspofungin; MICA, micafungin; ANI, anidulafungin; GC,
growth control.
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bility; it is the only isolate which shows some susceptibility
toward the echinocandins, especially against ANI. Mm41 is not
morphologically different from the other M. mycetomatis iso-
lates and has the same cellular beta-glucan quantity as the
other isolates. Furthermore, when this isolate was typed by
selective amplification of restriction fragments (amplified frag-
ment length polymorphism [AFLP]), this isolate clustered to-
gether with other M. mycetomatis isolates isolated from Sudan
and used in this study (9).
For A. fumigatus, growth was not completely inhibited by
high concentrations of the echinocandins. Only at very high
concentrations was lack of growth noticed (CAS [MIC of 128
mg/liter], ANI [MIC of 128 mg/liter], and MICA [MIC of 128
mg/liter]). At much lower concentrations, growth alteration
was noted (MEC of 0.125 mg/liter for CAS andMECs of 0.03
mg/liter for ANI andMICA) (Fig. 1C and D). Therefore, it was
investigated if alteration of growth also occurred in M. myce-
tomatis after exposure to the echinocandins. As shown in Fig.
1A and B, no growth alteration was observed under the tested
conditions when M. mycetomatis was exposed to CAS, ANI, or
MICA (the last two are not shown).
To confirm the lack of echinocandin activity against M. my-
cetomatis, -1,3-glucan production was determined in M. my-
cetomatis and A. fumigatus. As shown in Fig. 1, under the
experimental conditions, all three echinocandins were unable
to inhibit -1,3-D-glucan synthesis in M. mycetomatis. -1,3-D-
Glucan concentrations were documented for M. mycetomatis
isolates not exposed to an echinocandin that were similar to
those for M. mycetomatis isolates exposed to various echi-
nocandin concentrations, even in ANI-inhibited isolate
Mm41. In contrast, in A. fumigatus, the echinocandins did
inhibit -1,3-D-glucan synthesis as seen by the lowering
-1,3-D-glucan concentrations represented in Fig. 1F and
reported by Kahn et al. (3).
From our results, it appears that M. mycetomatis is not sus-
ceptible to the echinocandin class of antifungal agents. The
reason behind this intrinsic resistance was not explored in the
present study, but some clues might be obtained from other
fungi. Echinocandin agents are also ineffective against Fusar-
ium species, Cryptococcus neoformans, and agents of zygomy-
cosis. Resistance in Fusarium solani is shown to be partly
caused by certain amino acid substitutions in the protein en-
coded by the target gene fks1 (4). Differences in the fks1 gene
are not the only mechanism underlying echinocandin resis-
tance. In the caspofungin-resistant fungus C. neoformans, the
FKS enzyme itself was fully inhibited by low concentrations of
CAS (5). Since the echinocandins require transport into the
cell to their site of action, the surface properties of fungi might
contribute to resistance. Since C. neoformans is highly mela-
nized, it was hypothesized that this melanization could affect
echinocandin susceptibility (7). For M. mycetomatis, the fks1
sequence is not known, but it has been demonstrated that the
fungus can produce melanin both in vitro and in vivo. Further
study is needed to determine the mechanism of this resistance.
In conclusion, in our assay, the echinocandins CAS, ANI,
and MICA are not active against M. mycetomatis. There was no
inhibition in growth, growth alteration, or reduction in -1,3-
glucan biosynthesis noted for M. mycetomatis isolates after
exposure to these antifungal agents in the assays used. There-
fore, the therapeutic potential of the echinocandins in the
treatment of mycetoma infections caused by M. mycetomatis
remains doubtful.
We have no transparency declarations to declare.
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